Osborne Clarke has advised the shareholders of LYKON, a Berlin-based provider of home biomarker tests, on their sale to the Stockholm-founded nutrition app Lifesum. LYKON, established in 2018, specializes in personalized nutrition and medicine, offering DNA and blood tests for home use. Lifesum, founded in 2013, operates in 36 markets worldwide and is known for its nutrition app, which helps users develop sustainable dietary habits through personalized insights. This acquisition aims to revolutionize Europe’s wellbeing market with advanced personalized health solutions. The Osborne Clarke team, led by Maximilian Vocke, played a key role in advising LYKON’s shareholders during this transaction.

Digital Health, Personalized Medicine, Mergers and Acquisitions,Germany, Sweden

https://www.osborneclarke.com/news/osborne-clarke-advises-shareholders-lykon-sale-lifesum